SOPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SOPHiA GENETICS SA (SOPH) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock demonstrates positive financial growth trends, strong hedge fund interest, and bullish technical indicators, making it a solid entry point despite insider selling activity.
The technical indicators are bullish. The MACD is positive and contracting, the RSI is neutral at 36.2, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 4.99, with key support at 4.707 and resistance at 5.272.
Hedge funds have significantly increased their buying activity by 1033.12% over the last quarter. Analysts have raised price targets recently (BTIG to $8 and Guggenheim to $7), reflecting confidence in the company's business strategy and leadership.
Insider selling has increased by 2054.32% over the last month, which may indicate some caution from company insiders. Additionally, no recent news or major event-driven catalysts are present.
In Q4 2025, SOPH showed strong financial growth with revenue up 22.41% YoY to $21.71M, net income improving by 26.53% YoY to -$19.18M, and EPS increasing by 21.74% YoY to -0.28. However, gross margin slightly declined by 0.84% YoY to 67.68%.
Analysts maintain a Buy rating with increased price targets (BTIG: $8, Guggenheim: $7), citing confidence in the company's business outlook and management team.
